Seeking Alpha pitches Kailera as next obesity drug approval bet
Commentary frames the newly listed biotech as an outsider contender in the GLP-1 obesity race.
TR
By Tom Reyes · Markets Editor
Sep 17 11:42 ETSource: Seeking Alpha
The wire
- 01Investment commentary positions Kailera Therapeutics as a candidate for the next GLP-1 obesity approval.
- 02Reflects investor search for alternatives to Novo Nordisk and Eli Lilly.
- 03No regulatory filing or approval timeline is cited.
From the source
Read at news.google.comKailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval